How Eli Lilly, NVIDIA, and Other Big Pharma Companies Use AI for Drug Discovery in 2026
The AI for drug discovery market hit $8.8 billion in 2026 and is projected to reach $114.4 billion by 2033.
Why? Because big pharma just found a way to cut drug development from 10-15 years to 6 months.
In January 2026, Eli Lilly and NVIDIA announced a $1 billion AI co-innovation lab to reinvent drug discovery. But Lilly isn’t alone. Pfizer, Novartis, Roche, Sanofi, and AstraZeneca are all doubling down on AI in drug discovery to slash costs and timelines.
Here’s exactly how the top AI drug discovery companies are doing it in 2026.
1. AI in Target Discovery and Molecule Design: Exploring Billions of Compounds In Silico
The first breakthrough from AI drug discovery is in the lab’s earliest stage.
*Big pharma uses AI to analyze massive biological and chemical datasets to identify drug targets and predict drug–target interactions before any wet-lab testing. Instead of testing 1 million compounds physically, AI drug discovery platforms run virtual screening across vast chemical space.
How AI Accelerates Target Identification
- Target ID & Validation: AI scans genomics, proteomics, and clinical data to find proteins linked to disease
- Structure Prediction: Tools like AlphaFold support druggability assessment and structure-based design
- De Novo Molecule Generation: Generative models like LSTM-RNNs, VAEs, GANs, and reinforcement learning now create novel drug-like molecules
Eli Lilly + NVIDIA: The $1 Billion AI Lab
This is the biggest move in 2026. Eli Lilly and NVIDIA launched a co-innovation lab built on NVIDIA BioNeMo and Vera Rubin architecture.
The goal: a "continuous learning system" where Lilly’s wet labs and NVIDIA’s dry labs talk 24/7. As Jensen Huang said: "researchers can explore billions of possibilities in silico before a single experiment is run."
Lilly also launched TuneLab, an AI and machine learning platform trained on $1 billion+ of proprietary Lilly data. It’s now offered to biotechs to accelerate drug development.
Other big pharma AI partnerships: Takeda–Numerate, Sanofi–Exscientia, Pfizer–IBM Watson, Merck–Atomwise.
AI drug repurposing is where Eli Lilly has its clearest published win.
In early 2020, BenevolentAI used knowledge graphs and NLP to identify Lilly’s rheumatoid arthritis drug baricitinib as a potential COVID-19 treatment. It was later advanced by Lilly and used in hospitals worldwide.
- Healx advanced HLX-0201 for fragile X syndrome to Phase II in 18 months using AI
- AI pipelines also flagged oncology opportunities for cimetidine and bazedoxifene
Why it matters: AI drug repurposing skips years of safety testing. It’s one of the fastest ways AI in pharmaceutical companies delivers ROI.
AI for drug discovery doesn’t stop at the molecule. The biggest savings happen in development.
Pfizer used AI to predict drug–drug interactions from structural and clinical datasets. Reviews estimate AI can speed discovery by 1-2 years.
They’re also pioneering robotics and physical AI to scale production of high-demand drugs. Novartis applied AI to formulation optimization. Roche used patient-specific data for personalized response prediction.
The goal: a "continuous learning system" where Lilly’s wet labs and NVIDIA’s dry labs talk 24/7. As Jensen Huang said: "researchers can explore billions of possibilities in silico before a single experiment is run."
Lilly also launched TuneLab, an AI and machine learning platform trained on $1 billion+ of proprietary Lilly data. It’s now offered to biotechs to accelerate drug development.
Other big pharma AI partnerships: Takeda–Numerate, Sanofi–Exscientia, Pfizer–IBM Watson, Merck–Atomwise.
2. AI Drug Repurposing: Finding New Uses for Old Drugs in Weeks
AI drug repurposing is where Eli Lilly has its clearest published win.
In early 2020, BenevolentAI used knowledge graphs and NLP to identify Lilly’s rheumatoid arthritis drug baricitinib as a potential COVID-19 treatment. It was later advanced by Lilly and used in hospitals worldwide.
Other AI Repurposing Examples in Big Pharma
- Johnson & Johnson used BenevolentAI to repurpose bavisant for Parkinson’s-related daytime sleepiness- Healx advanced HLX-0201 for fragile X syndrome to Phase II in 18 months using AI
- AI pipelines also flagged oncology opportunities for cimetidine and bazedoxifene
Why it matters: AI drug repurposing skips years of safety testing. It’s one of the fastest ways AI in pharmaceutical companies delivers ROI.
3. AI in Clinical Trials, ADMET, and Manufacturing: Cutting 2 Years Off Development
AI for drug discovery doesn’t stop at the molecule. The biggest savings happen in development.
AI for Clinical Development and ADMET
Big pharma uses AI to improve patient selection, predict drug–drug interactions, and model ADMET - absorption, distribution, metabolism, excretion, toxicity.Pfizer used AI to predict drug–drug interactions from structural and clinical datasets. Reviews estimate AI can speed discovery by 1-2 years.
AI in Manufacturing and Digital Twins with NVIDIA
This is the 2026 game changer. Lilly announced the most powerful AI factory in pharma. Using *NVIDIA Omniverse and RTX PRO servers, Lilly builds digital twins of manufacturing lines to model and optimize supply chains.They’re also pioneering robotics and physical AI to scale production of high-demand drugs. Novartis applied AI to formulation optimization. Roche used patient-specific data for personalized response prediction.
Key AI Drug Discovery Companies and Their 2026 Strategies
| Company | How They Use AI in Drug Discovery | 2026 Example |
|---|---|---|
| Eli Lilly | AI platform, supercomputer, repurposing | Baricitinib, TuneLab, $1B lab with NVIDIA |
| Pfizer | ML discovery, manufacturing AI | IBM Watson, AI for vaccine yield |
| Novartis | Formulation optimization, multi-omics | AI for drug delivery |
| Roche | Personalized medicine | Patient-specific AI models |
| Sanofi, AstraZeneca, GSK, Merck | Partnerships with AI firms | Exscientia, Insilico Medicine, Valo Health |
/>Even OpenAI launched GPT-Rosalind in April 2026, a model purpose-built for chemistry and protein engineering for pharma giants like Amgen and Moderna.
Industry forecasts say machine learning to optimize target discovery could halve early-stage development timelines and costs within 3-5 years.
Big pharma is betting that AI drug discovery will:
1. Explore chemical space before touching a test tube
2. Accelerate drug repurposing in weeks not years
3. Use AI + robotics to manufacture at scale
David Ricks of Lilly: "Combining our data with NVIDIA’s computational power could reinvent drug discovery as we know it."
AI hasn’t delivered an FDA-approved de novo drug yet. But it has already found life-saving repurposed drugs, cut timelines, and saved billions.
The race isn’t who discovers the next drug. It’s who builds the best AI for drug discovery to discover it first.
Want the technical breakdown of how AI models are trained on molecular data, ADMET prediction, and foundation models for chemistry?
--
The Future of AI in Pharma: $30 Billion Market by 2040
Industry forecasts say machine learning to optimize target discovery could halve early-stage development timelines and costs within 3-5 years.
Big pharma is betting that AI drug discovery will:
1. Explore chemical space before touching a test tube
2. Accelerate drug repurposing in weeks not years
3. Use AI + robotics to manufacture at scale
David Ricks of Lilly: "Combining our data with NVIDIA’s computational power could reinvent drug discovery as we know it."
Expert Opinion: Where Is AI Drug Discovery Headed After 2026?
In my view, the biggest bottleneck for AI drug discovery in 2026 isn’t the algorithms. It’s the data. Companies like Eli Lilly have a 100-year advantage because they own billions of proprietary wet-lab results that no AI startup can access. That’s why the $1 billion Lilly-NVIDIA lab matters so much — it’s the first time pharma data meets supercomputing at scale.
Second, we still haven’t seen a true de novo drug — 100% designed by AI — get FDA approval. 2027 and 2028 will be the test years. If that happens, the market won’t stop at $114.4 billion. We’re looking at a $300+ billion industry almost overnight.
The winners won’t be the companies with the best AI. They’ll be the companies with the best data + the best AI + the fastest manufacturing. That’s exactly the bet Lilly and NVIDIA are making right now.
Final Thoughts: Why AI Drug Discovery Matters in 2026
AI hasn’t delivered an FDA-approved de novo drug yet. But it has already found life-saving repurposed drugs, cut timelines, and saved billions.
The race isn’t who discovers the next drug. It’s who builds the best AI for drug discovery to discover it first.
Want the technical breakdown of how AI models are trained on molecular data, ADMET prediction, and foundation models for chemistry?
--
